时间：2026-09-24 02:04:12 来源：Urban Hub

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Hopeful Breakthrough Pill Tested in Both Forms of Common Inherited Heart Disease**

*Phase‑2 data on EDG‑7500 were presented in Munich, covering both forms of hypertrophic cardiomyopathy. The drug remains investigational and unapproved.*

---

### Introduction

At the 2024 European Cardiology Congress in Munich, biotech firm **EvoGenix Therapeutics** unveiled interim results from a Phase‑2 trial of its novel oral agent **EDG‑7500**. The compound was evaluated in patients with the two most prevalent genetic variants of **hypertrophic cardiomyopathy (HCM)**—the obstructive (oHCM) and non‑obstructive (nHCM) phenotypes. With an estimated 1 in 500 people worldwide carrying the mutation, HCM remains a leading cause of sudden cardiac death in young adults. The presentation marks the first time a single molecule has been tested across both disease subtypes in a controlled setting.

### Key Developments

- **Efficacy signals**: In the 120‑patient cohort, EDG‑7500 produced a mean reduction of 8 mm Hg in left‑ventricular outflow tract gradient for oHCM participants and a 12 % improvement in peak oxygen uptake (VO₂ max) for nHCM subjects.
- **Safety profile**: Adverse events were limited to mild gastrointestinal upset in 9 % of participants; no serious cardiac arrhythmias were reported.
- **Biomarker response**: Serum levels of N‑terminal pro‑BNP fell by an average of 22 % across the trial, indicating a favorable effect on cardiac stress.

EvoGenix’s Chief Medical Officer, Dr. Lena Kraus, emphasized that “the dual‑phenotype design of this study reflects real‑world practice, where clinicians must manage both obstructive and non‑obstructive HCM with a single therapeutic strategy.”

### Industry Analysis

The HCM market, valued at roughly **$2.3 billion** in 2023, is dominated by surgical septal myectomy, alcohol septal ablation, and a handful of FDA‑approved myosin inhibitors such as mavacamten. However, existing drugs are limited by dosing complexities, drug‑drug interactions, and high cost. EDG‑7500’s oral formulation and apparent tolerability could disrupt this landscape, especially if Phase‑3 trials confirm the early efficacy signals.

Analysts at **MediBridge Research** note that “a pill that

上一篇：Samsung Battery Drain Nightmare? Discover the One UI 8.5 Shocking Fix
下一篇：Finland's Shocking AI-Era Defense Plan: Why Retail is Now a National Security Priority

• ·Google Revolutionizes Autofill on iOS and Android with Chrome Upgrade
• ·Da Nang City Takes Firm Stand Against Sidewalk Encroachment and Chaos
• ·Singapore Firms Rely Heavily on Govt Support Amid Rising Geopolitical Tensions
• ·Saudi Arabia's Oil Output and Pipeline Flow Severely Disrupted by Attacks
• ·LayerNav Android Library Updated to 0.5.6: What's New and Improved?
• ·Cristiano Ronaldo Eyes Sixth World Cup with Unfinished Glory to Claim
• ·BlackRock-Backed Mining Giant Ditches $200 Billion Deal in Africa's Mineral Rush
• ·Singapore Stocks Plunge: Banking Sector Losses Weigh Heavily on Market
• ·Cardano Users Reeling as SecondFi Hack Results in $20M+ Devastating Loss
• ·Wall Street Plummets: Trump's Tariff Threat Sparks Panic Selloff Amid Market Turmoil
• ·BlackRock-Backed Mining Giant Ditches $200 Billion Deal in Africa's Mineral Rush
• ·Volatus Aerospace Unveils Q1 2026 Financials: Earnings Call on May 14
• ·Woodlands Hospital Appoints New CEO, Revolutionizing Healthcare from February 1st
• ·Revolutionary Apple iPhone Fold Ultra Leaves Tech World Stunned and Intrigued
• ·Singapore Stocks Plunge: Banking Sector Losses Weigh Heavily on Market
• ·Singapore Stocks Plunge: Banking Sector Losses Weigh Heavily on Market